GlassScriptPhysician profile
Diane K Wetherton
NPI 1538135603
$1,285.49
in general payments reported to CMS, 2019-2025
24 companies · $227 in 2025
The $227 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $133 · 2021: $129 · 2022: $28.50 · 2023: $224 · 2024: $227 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $166.06 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Ironshore Pharmaceuticals INC. | $129.92 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $123.76 | 2020-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Tris Pharma INC | $118.75 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $93.13 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $89.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.28 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $67.49 | 2024 | Qelbree |
| Rhodes Pharmaceuticals L.P. | $54.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $50.94 | 2023 | |
| Neos Therapeutics, LP | $34.20 | 2019-2021 | |
| Cranial Technologies, INC | $33.14 | 2024 | Doc Band |
| Sobi, INC | $28.97 | 2019-2020 | |
| Pfizer INC. | $27.67 | 2019-2023 | |
| Adlon Therapeutics L.P. | $25.13 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $24.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.24 | 2025 | |
| Circassia INC. | $18.83 | 2019 | |
| Shire North American Group INC | $18.42 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.36 | 2024 | |
| Seqirus USA INC | $17.59 | 2021 | |
| Corium, LLC | $16.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.88 | 2025 | Zoryve |
| Genentech USA, INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Wetherton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.